As we observed a high proliferation of CD4+ T cells induced by DC-based lung cancer vaccine, it is tempting to speculate that CD4+ T cells might play an important role in shaping anti-cancer responses after DC-based HHP lung cancer immunotherapy in NSCLC patients. This evidence concerns the gene CD4 and lung carcinoma.